Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : CSC-RI00210
Host Cell : HEK293 Size : >1x106 frozen cells/vial
| Cat. No. | CSC-RI00210 |
| Description | This cell line is engineered to stably express Homo sapiens (human) transient receptor potential cation channel subfamily V member 6 (TRPV6) in Human immortalized embryonic kidney cell line (HEK293). GFP reporter gene is also expressed in this cell line allowing fluorescent tracking of cells. |
| Product Type | Human gene overexpression stable cell line |
| Target Gene | TRPV6 |
| Gene Species | Homo sapiens (human) |
| Host Cell | HEK293 |
| Host Cell Species | Homo sapiens (Human) |
| Reporter | GFP |
| Applications |
1) investigation of gene function 2) screening and validation of antibodies |
| Size | One vial of frozen cells, typically >1x10^6cells/vial |
| Stability | This cell line is stable at least 10 passages. |
| Quality Control |
1) Real-time qPCR analysis of gene mRNA overexpression level 2) GFP fluorescent detection under fluorescent microscopy 3) mycoplasma detection |
| Storage | Liquid nitrogen |
| Shipping | Dry ice |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Growth Properties | Adherent |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
| Target Gene | TRPV6 |
| Background | This gene encodes a member of a family of multipass membrane proteins that functions as calcium channels. The encoded protein contains N-terminal ankyrin repeats, which are required for channel assembly and regulation. Translation initiation for this protein occurs at a non-AUG start codon that is decoded as methionine. This gene is situated next to a closely related gene for transient receptor potential cation channel subfamily V member 5 (TRPV5). This locus has experienced positive selection in non-African populations, resulting in several non-synonymous codon differences among individuals of different genetic backgrounds. [provided by RefSeq, Feb 2015] |
The Transient Receptor Potential Vanilloid 6 (TRPV6) gene encodes an ion channel characterized by high calcium selectivity, playing a pivotal role in maintaining systemic and intracellular calcium homeostasis within the human body. Originally identified as a calcium transporter in intestinal epithelial cells, the membrane channel produced by TRPV6 facilitates the active apical uptake of calcium ions across the epithelial barriers of the gastrointestinal tract, renal tubules, and placenta. Unlike many other members of the TRP channel superfamily—which are activated by temperature, mechanical stress, or specific chemical ligands—TRPV6 is considered a constitutively active channel. Its activity is primarily and strictly regulated by factors such as intracellular calcium levels, calmodulin binding, and hormonal signals, including active vitamin D. It is frequently classified as an "oncochannel" because TRPV6 gene expression levels are significantly upregulated in a wide range of aggressive human malignancies, including prostate, breast, colon, thyroid, and ovarian cancers. Consequently, the TRPV6 channel serves not only as a highly promising and validated therapeutic target for the development of novel targeted anticancer drugs but also as a potential diagnostic and prognostic biomarker for monitoring tumor progression.
The human TRPV6 stable cell line, established within a HEK293 cell background, was generated by stably transfecting a meticulously engineered expression vector—containing the full-length human TRPV6 coding sequence—into Human Embryonic Kidney 293 (HEK293) cells, followed by a rigorous clonal screening process to ensure phenotypic consistency. The resulting stable cell line achieves reliable, robust, and sustained expression of functional TRPV6 protein on the plasma membrane, thereby effectively overcoming the technical challenges commonly associated with traditional transient transfection protocols—specifically, high technical variability, low target protein yield, and time-consuming procedures. This cell line is widely utilized in high-throughput screening initiatives across both industrial and academic sectors to rapidly identify, optimize, and evaluate novel TRPV6 modulators—particularly potential small-molecule antagonists that hold promise as next-generation cancer therapeutics. Researchers extensively utilize these stable cell lines for functional calcium mobilization assays, frequently employing fluorescent intracellular calcium indicators—such as Fluo-4 or Fura-2—to enable precise, real-time monitoring of channel activity, dose-response relationships, and the overall efficacy of therapeutic agents.
Maternal-fetal calcium ion (Ca2+) transport across the placenta plays a crucial role in maintaining fetal skeletal mineralization. Mutations in the gene encoding Transient Receptor Potential Cation Channel, Subfamily V, Member 6 (TRPV6) have been identified as pathogenic mutations responsible for transient neonatal hyperparathyroidism-a condition etiologically linked to insufficient maternal-fetal Ca2+ transport across the placenta. Here, researchers identified two novel mutations in subjects presenting with transient neonatal hyperparathyroidism. The TRPV6 protein harboring the p.Arg390His mutation is localized to the outer edge of the first transmembrane domain (S1); this mutation results in impaired trafficking of the protein to the plasma membrane. In contrast, the TRPV6 protein carrying the p.Gly291Ser mutation-located within the sixth ankyrin repeat (AR) domain-exhibits channel properties comparable to those of the wild-type (WT) channel; however, it leads to elevated intracellular steady-state Ca2+ concentrations, which may trigger Ca2+ overload and subsequently induce cell death in cells expressing this mutant channel. These findings suggest that the AR6 domain contributes to TRPV6-mediated maintenance of intracellular Ca2+ concentrations and may play a novel role in regulating the activity of the Ca2+-selective TRPV6 channel.
To analyze the biological significance of the p.Gly291Ser and p.Arg390His mutations, researchers transfected HEK293T cells with expression vectors carrying the mutant forms of TRPV6 and performed whole-cell patch-clamp recordings 20–24 hours post-transfection. HEK293T cells expressing the p.Gly291Ser mutant generated inducible currents upon exposure to either a divalent-free (DVF) bath solution or a high-Ca²⁺ bath solution; the characteristics of these currents were similar to those observed in wild-type TRPV6-expressing HEK293T cells (Figure 1a, c). In this experiment, the researchers utilized an NMDG solution devoid of Ca²⁺ and Mg²⁺ to facilitate a clearer observation of Ca²⁺ currents. No differences were observed between wild-type TRPV6-expressing HEK293T cells and p.Arg390His mutant-expressing cells regarding their current-voltage relationships or reversal potentials (Figure 1b), suggesting that both exhibit similar ion selectivity. Furthermore, no significant differences were detected between the two groups in intracellular Ca²⁺-dependent inactivation, at least within the 20–30-second timeframe of the patch-clamp recordings (Figure 1d). These results suggest that the apparent channel properties of the Gly291Ser mutant have been preserved. In contrast, in cells expressing the p.Arg390His mutant, neither the DVF bath solution nor the high-Ca²⁺ bath solution was able to induce any detectable current (Figure 1c).
Figure 1. Whole-cell patch-clamp recordings in TRPV6-expressing HEK293T cells. (Suzuki Y, et al., 2020)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
For our electrophysiology experiments, consistency is key. This TRPV6 HEK293 line provides stable calcium currents and responds predictably to known inhibitors. It saved us months of work in stable cell line development.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.